MARKET

CLDX

CLDX

Celldex Therapeutics Inc
NASDAQ
36.66
-0.68
-1.82%
After Hours: 36.66 0 0.00% 16:46 12/05 EST
OPEN
37.02
PREV CLOSE
37.34
HIGH
37.37
LOW
35.78
VOLUME
604.63K
TURNOVER
0
52 WEEK HIGH
42.46
52 WEEK LOW
19.85
MARKET CAP
1.73B
P/E (TTM)
-16.1840
1D
5D
1M
3M
1Y
5Y
BRIEF-Celldex Therapeutics Presents Positive Data From Barzolvolimab Phase 1b Study In Chronic Inducible Urticaria
Reuters · 14h ago
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022
- 100% complete response rate in cold urticaria after single dose of barzolvolimab at 1.5 mg/kg, including in omalizumab refractory patients -- Long term follow up of patients with chronic inducible urticaria treated at 3.0 mg/kg confirm that barzolvolimab...
GlobeNewswire · 15h ago
Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022
- Includes oral presentation for 1.5 mg/kg cold urticaria cohort - - Company to host webcast conference call on Tuesday, December 6 at 8:00 am ET - HAMPTON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today th...
GlobeNewswire · 4d ago
We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Simply Wall St. · 11/27 14:45
Guggenheim Maintains Buy on Celldex Therapeutics, Lowers Price Target to $63
Benzinga · 11/11 13:51
--Guggenheim Adjusts Price Target on Celldex Therapeutics to $63 From $68, Maintains Buy Rating
--Guggenheim Adjusts Price Target on Celldex Therapeutics to $63 From $68, Maintains Buy Rating
MT Newswires · 11/11 09:53
Celldex to Participate in Upcoming November Investor Conferences
HAMPTON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following investor conferences in November: Guggenheim 4th Annual Immunology and Neurology C...
GlobeNewswire · 11/10 21:01
Celldex GAAP EPS of -$0.57 beats by $0.01, revenue of $0.41M beats by $0.05M
Seekingalpha · 11/09 22:01
More
About CLDX
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Company is using the technologies to develop targeted immunotherapeutics consisting of protein-based molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. It operates in development, manufacturing of therapeutics. Company's CDX-0159, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity. Its CDX-1140, an agonist monoclonal antibody targeted to CD40, a key activator of immune response, being studied in a Phase II study. The Company's CDX-527, a bispecific antibody that uses active anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, for which it initiated a Phase II study in advanced solid tumors.

Webull offers kinds of Celldex Therapeutics, Inc. stock information, including NASDAQ:CLDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLDX stock methods without spending real money on the virtual paper trading platform.